International Renal Research Institute of Vicenza, Vicenza, Italy.
Department of Nephrology, San Bortolo Hospital, Vicenza, Italy.
Contrib Nephrol. 2023;200:66-73. doi: 10.1159/000529313. Epub 2023 Jun 1.
Sorbents have been utilized in the past for intoxication and poisoning, but their spectrum of clinical application is now expanding. Hemoadsorption (HA) is still indicated for toxin and poison removal, but other molecules are considered appropriate targets for this blood purification modality. HA combined with hemodialysis (HA + HD) has been proposed for end-stage kidney disease patients to remove molecules that are not easily removed by classic HD or hemodiafiltration. More recently, a rationale for the use of sorbents in critical illness, sepsis, and acute kidney injury has emerged due to the proposed humoral theory behind these disorders. Pathogenetic circulating molecules in critical illness (damage- and pathogen-associated molecular patterns) cannot be sufficiently removed by classic continuous renal replacement therapies. New sorbent-based extracorporeal therapies have therefore been designed to remove these molecules, offering potential biological and clinical benefits. There is also the possibility of employing selective sorbents to target specific molecules or to perform nonspecific HA for a wide spectrum of molecules. Moreover, there is the possibility of separating plasma from blood and then applying adsorption to plasma or of combining HA with other extracorporeal therapies. Here, we describe a complete appraisal of current available techniques utilizing adsorption.
吸附剂过去曾被用于中毒和中毒,但它们的临床应用范围现在正在扩大。血液吸附(HA)仍然适用于毒素和毒物的清除,但其他分子也被认为是这种血液净化方式的合适靶标。HA 与血液透析(HA + HD)联合已被提议用于终末期肾病患者,以去除经典血液透析或血液透析滤过不易清除的分子。最近,由于这些疾病背后提出的体液理论,吸附剂在危重病、脓毒症和急性肾损伤中的应用有了合理依据。危重病中的致病性循环分子(损伤和病原体相关分子模式)不能被经典的连续肾脏替代疗法充分清除。因此,设计了新的基于吸附剂的体外治疗方法来清除这些分子,提供潜在的生物学和临床益处。还可以使用选择性吸附剂针对特定分子,或针对广泛的分子进行非特异性 HA。此外,还有可能将血浆从血液中分离出来,然后对血浆进行吸附,或者将 HA 与其他体外治疗方法结合使用。在这里,我们描述了对当前使用的吸附技术的全面评估。